Cargando…

The Abscopal Effect in the Era of Checkpoint Inhibitors

Therapy targeting immune checkpoints represents an integral part of the treatment for patients suffering from advanced melanoma. However, the mechanisms of resistance are responsible for a lower therapeutic outcome than expected. Concerning melanoma, insufficient stimulation of the immune system by...

Descripción completa

Detalles Bibliográficos
Autores principales: Kodet, Ondřej, Němejcova, Kristýna, Strnadová, Karolína, Havlínová, Andrea, Dundr, Pavel, Krajsová, Ivana, Štork, Jiří, Smetana, Karel, Lacina, Lukáš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267720/
https://www.ncbi.nlm.nih.gov/pubmed/34281259
http://dx.doi.org/10.3390/ijms22137204
_version_ 1783720204643074048
author Kodet, Ondřej
Němejcova, Kristýna
Strnadová, Karolína
Havlínová, Andrea
Dundr, Pavel
Krajsová, Ivana
Štork, Jiří
Smetana, Karel
Lacina, Lukáš
author_facet Kodet, Ondřej
Němejcova, Kristýna
Strnadová, Karolína
Havlínová, Andrea
Dundr, Pavel
Krajsová, Ivana
Štork, Jiří
Smetana, Karel
Lacina, Lukáš
author_sort Kodet, Ondřej
collection PubMed
description Therapy targeting immune checkpoints represents an integral part of the treatment for patients suffering from advanced melanoma. However, the mechanisms of resistance are responsible for a lower therapeutic outcome than expected. Concerning melanoma, insufficient stimulation of the immune system by tumour neoantigens is a likely explanation. As shown previously, radiotherapy is a known option for increasing the production of tumour neoantigens and their release into the microenvironment. Consequently, neoantigens could be recognized by antigen presenting cells (APCs) and subjected to effector T lymphocytes. Enhancing the immune reaction can trigger the therapeutic response also at distant metastases, a phenomenon known as an abscopal effect (from “ab scopus”, that is, away from the target). To illustrate this, we present the case of a 78-year old male treated by anti-CTLA-4/ipilimumab for metastatic melanoma. The patient received the standard four doses of ipilimumab administered every three weeks. However, the control CT scans detected disease progression in the form of axillary lymph nodes metastasis and liver metastasis two months after ipilimumab. At this stage, palliative cryotherapy of the skin metastases was initiated to alleviate the tumour burden. Surprisingly, the effect of cryotherapy was also observed in untreated metastases and deep subcutaneous metastases on the back. Moreover, we observed the disease remission of axillary lymph nodes and liver metastasis two months after the cryotherapy. The rarity of the abscopal effect suggests that even primed anti-tumour CD8(+) T cells cannot overcome the tumour microenvironment’s suppressive effect and execute immune clearance. However, the biological mechanism underlying this phenomenon is yet to be elucidated. The elicitation of a systemic response by cryotherapy with documented abscopal effect was rarely reported, although the immune response induction is presumably similar to a radiotherapy-induced one. The report is a combination case study and review of the abscopal effect in melanoma treated with checkpoint inhibitors.
format Online
Article
Text
id pubmed-8267720
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82677202021-07-10 The Abscopal Effect in the Era of Checkpoint Inhibitors Kodet, Ondřej Němejcova, Kristýna Strnadová, Karolína Havlínová, Andrea Dundr, Pavel Krajsová, Ivana Štork, Jiří Smetana, Karel Lacina, Lukáš Int J Mol Sci Article Therapy targeting immune checkpoints represents an integral part of the treatment for patients suffering from advanced melanoma. However, the mechanisms of resistance are responsible for a lower therapeutic outcome than expected. Concerning melanoma, insufficient stimulation of the immune system by tumour neoantigens is a likely explanation. As shown previously, radiotherapy is a known option for increasing the production of tumour neoantigens and their release into the microenvironment. Consequently, neoantigens could be recognized by antigen presenting cells (APCs) and subjected to effector T lymphocytes. Enhancing the immune reaction can trigger the therapeutic response also at distant metastases, a phenomenon known as an abscopal effect (from “ab scopus”, that is, away from the target). To illustrate this, we present the case of a 78-year old male treated by anti-CTLA-4/ipilimumab for metastatic melanoma. The patient received the standard four doses of ipilimumab administered every three weeks. However, the control CT scans detected disease progression in the form of axillary lymph nodes metastasis and liver metastasis two months after ipilimumab. At this stage, palliative cryotherapy of the skin metastases was initiated to alleviate the tumour burden. Surprisingly, the effect of cryotherapy was also observed in untreated metastases and deep subcutaneous metastases on the back. Moreover, we observed the disease remission of axillary lymph nodes and liver metastasis two months after the cryotherapy. The rarity of the abscopal effect suggests that even primed anti-tumour CD8(+) T cells cannot overcome the tumour microenvironment’s suppressive effect and execute immune clearance. However, the biological mechanism underlying this phenomenon is yet to be elucidated. The elicitation of a systemic response by cryotherapy with documented abscopal effect was rarely reported, although the immune response induction is presumably similar to a radiotherapy-induced one. The report is a combination case study and review of the abscopal effect in melanoma treated with checkpoint inhibitors. MDPI 2021-07-04 /pmc/articles/PMC8267720/ /pubmed/34281259 http://dx.doi.org/10.3390/ijms22137204 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kodet, Ondřej
Němejcova, Kristýna
Strnadová, Karolína
Havlínová, Andrea
Dundr, Pavel
Krajsová, Ivana
Štork, Jiří
Smetana, Karel
Lacina, Lukáš
The Abscopal Effect in the Era of Checkpoint Inhibitors
title The Abscopal Effect in the Era of Checkpoint Inhibitors
title_full The Abscopal Effect in the Era of Checkpoint Inhibitors
title_fullStr The Abscopal Effect in the Era of Checkpoint Inhibitors
title_full_unstemmed The Abscopal Effect in the Era of Checkpoint Inhibitors
title_short The Abscopal Effect in the Era of Checkpoint Inhibitors
title_sort abscopal effect in the era of checkpoint inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267720/
https://www.ncbi.nlm.nih.gov/pubmed/34281259
http://dx.doi.org/10.3390/ijms22137204
work_keys_str_mv AT kodetondrej theabscopaleffectintheeraofcheckpointinhibitors
AT nemejcovakristyna theabscopaleffectintheeraofcheckpointinhibitors
AT strnadovakarolina theabscopaleffectintheeraofcheckpointinhibitors
AT havlinovaandrea theabscopaleffectintheeraofcheckpointinhibitors
AT dundrpavel theabscopaleffectintheeraofcheckpointinhibitors
AT krajsovaivana theabscopaleffectintheeraofcheckpointinhibitors
AT storkjiri theabscopaleffectintheeraofcheckpointinhibitors
AT smetanakarel theabscopaleffectintheeraofcheckpointinhibitors
AT lacinalukas theabscopaleffectintheeraofcheckpointinhibitors
AT kodetondrej abscopaleffectintheeraofcheckpointinhibitors
AT nemejcovakristyna abscopaleffectintheeraofcheckpointinhibitors
AT strnadovakarolina abscopaleffectintheeraofcheckpointinhibitors
AT havlinovaandrea abscopaleffectintheeraofcheckpointinhibitors
AT dundrpavel abscopaleffectintheeraofcheckpointinhibitors
AT krajsovaivana abscopaleffectintheeraofcheckpointinhibitors
AT storkjiri abscopaleffectintheeraofcheckpointinhibitors
AT smetanakarel abscopaleffectintheeraofcheckpointinhibitors
AT lacinalukas abscopaleffectintheeraofcheckpointinhibitors